RxDoctor Payments Data

Monique Barbour, MD

Ophthalmology · Lake Worth Fl, FLNPI 1043398175

Payments from drug & device makers

$278,415in general payments, 2019–2025

Across 651 payments — averaging $427.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$96K
  • Boehringer Ingelheim International GmbH$89K
  • GSK$38K
  • Oyster Point Pharma, Inc.$20K
  • Thea Pharma Inc.$9K
  • AbbVie$6K
  • plus $20K from 31 others

What the payments were for

  • Consulting fees$19,19513%
  • Speaking & faculty fees$95,88063%
  • Travel & lodging$15,46510%
  • Food & beverage$20,54614%
  • Education$1450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$278,415 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$92,863
Medicare patients
137
Services billed
867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine236$226,977
CequaCyclosporine235$168,984
VabysmoFaricimab-Svoa30$86,202
XiidraLifitegrast44$48,579
TyrvayaVarenicline Tartrate70$46,897
CombiganBrimonidine Tartrate/Timolol136$45,014
EyleaAflibercept11$35,150
XdemvyLotilaner18$34,379
RocklatanNetarsudil Mesylat/Latanoprost24$19,267
LumiganBimatoprost39$17,945
Cyclosporine52$17,181
MieboPerfluorohexyloctane/Pf16$15,860
Alphagan PBrimonidine Tartrate45$14,091
RhopressaNetarsudil Mesylate26$13,204
IyuzehLatanoprost/Pf31$10,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Lumigan, Alphagan P$6,338$304,027456 claims
Sun Pharmaceutical Industries Inc.Cequa$96,426$168,984235 claims
Genentech USA, Inc.Vabysmo$240$86,20230 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$4,611$64,43960 claims
Oyster Point Pharma, Inc.Tyrvaya$19,674$46,89770 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$1,862$34,37918 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$225$32,47150 claims
Thea Pharma Inc.Iyuzeh$8,671$10,15331 claims
AlconSimbrinza$985$4,62120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Lake Worth Fl

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →